A double-blind randomized phase II dose-finding study of olanzapine 10  mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy

ConclusionsBoth doses of 10 and 5  mg olanzapine provided a significant improvement in delayed emesis. A dose of 5 mg olanzapine was determined as the recommended dose for a further phase III study based on higher CR and lower somnolence rates.Clinical Trial InformationUMIN000014214
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research